Elanco Animal Health Incorporated· ELAN
🇺🇸 US · LargeSP400NYSE
- Price
- $25.58
- Day
- -0.54%
- Mkt Cap
- $12.78B
- 52W Range
- $13.76 – $27.72
- Volume
- 7.05M
- Beta
- 1.69
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Report highlights Elanco's impact through innovation, expanded access to animal care, a stronger and more sustainable food system and investment in people and communities INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today released its 2025 Impact Report, "Leading with Purpose," highlighting how the company brings together purpose, innovation and business strategy to help address some of society's most pressing challenges. The report details Elanco's progress across four interconnected areas: going beyond for animals, customers, society and its people.
Read full article
On July 29, 2026, Elanco Animal Health Inc (ELAN) shares rose 3.4% to $26.39, continuing a positive trend in the stock's price performance. Over the past year,
Read full article
Elanco Animal Health (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
California Public Employees Retirement System cut its stake in shares of Elanco Animal Health Incorporated (NYSE: ELAN) by 4.1% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 830,209 shares of the company's stock after selling 35,888 shares during the period. California Public
Read full article
Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro: Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours of treatment.i Kills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest3 initial speed of tick kill compared to the competition.ii Achieves a rapid speed of kill4 on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.i,ii Outlasts competitors whose speed of kill2,4 performance declined at the end of the month.i,ii INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- When it comes to killing ticks, veterinarians and pet owners want it done fast. New data published in Parasites & Vectors, a leading peer-reviewed publication, demonstrates that Elanco Animal Health's (NYSE: ELAN) Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) kills ticks1 faster2 than leading competitors Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets).i Newly Published Data Found Credelio Quattro: Faster 2 Tick 1 Speed of Kill: Credelio Quattro is the only product proven to significantly reduce black-legged ticks within 8 hours.i Lotilaner, the active ingredient in Credelio Quattro also has the fastest initial tick speed of kill against the lone star tick - in just 12 hours – and sustains the advantage throughout the dosing interval.ii Outperforms the Competition: Outperforms Simparica Trio® (12 hours) and NexGard® Plus (24 hours) at the end of the dosing period (Day 28).i Consistency Over Competitors: Achieves 8-hour speed of kill1 on Day 0 and on Day 28 with no performance drop-off.
Read full article
Does Elanco Animal Health Incorporated (ELAN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read full article
Allspring Global Investments Holdings LLC acquired a new position in Elanco Animal Health Incorporated (NYSE: ELAN) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,871,561 shares of the company's stock, valued at approximately $66,390,000. Allspring Global Investments Holdings LLC owned 0.58%
Read full article
Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read full article